^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Ibrance (palbociclib)

    i
    Company:
    Amgen, Pfizer
    Drug class:
    CDK4/6 inhibitor
    Related drugs:
    Apply
    Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial (NCT05564377)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    04/07/2023
    Primary completion :
    07/01/2030
    Completion :
    07/01/2030
    BRAF
    |
    Lynparza (olaparib) • Ibrance (palbociclib) • paclitaxel • Vectibix (panitumumab) • Koselugo (selumetinib) • Nerlynx (neratinib) • Piqray (alpelisib) • Lumakras (sotorasib) • Mektovi (binimetinib) • Tasigna (nilotinib) • fulvestrant • oxaliplatin • ipatasertib (RG7440) • leucovorin calcium • fluorouracil topical
    First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors (STX-478-101) (NCT05768139)
    Phase 1/2
    Scorpion Therapeutics, Inc.
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    04/17/2023
    Primary completion :
    02/28/2027
    Completion :
    02/28/2029
    PIK3CA
    |
    PIK3CA mutation
    |
    Ibrance (palbociclib) • Kisqali (ribociclib) • fulvestrant • STX-478
    Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial (NCT05554367)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    12/13/2023
    Primary completion :
    08/26/2026
    Completion :
    08/26/2026
    KRAS • BRAF • NRAS • HRAS • RAS
    |
    BRAF V600E • KRAS mutation • KRAS G12C • HRAS mutation • KRAS G12
    |
    Ibrance (palbociclib) • Mektovi (binimetinib)
    Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer (ELEVATE) (NCT05563220)
    Phase 1/2
    Stemline Therapeutics, Inc.
    Recruiting
    Last update posted :
    02/18/2025
    Initiation :
    01/24/2023
    Primary completion :
    12/27/2026
    Completion :
    12/28/2028
    HER-2 • ER • PIK3CA • CDK4
    |
    PIK3CA mutation
    |
    Ibrance (palbociclib) • everolimus • Piqray (alpelisib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • Truqap (capivasertib) • Orserdu (elacestrant)
    Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis (ASPIRE) (NCT03691493)
    Phase 2
    Emory University
    Completed
    Last update posted :
    02/17/2025
    Initiation :
    02/08/2019
    Primary completion :
    10/13/2022
    Completion :
    10/13/2022
    HER-2 • ER • PGR
    |
    ER positive • HER-2 negative • PGR positive
    |
    Ibrance (palbociclib) • fulvestrant • letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)
    A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer (MORPHEUS BC) (NCT04802759)
    Phase 1/2
    Hoffmann-La Roche
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    06/22/2021
    Primary completion :
    11/30/2027
    Completion :
    11/30/2027
    ER • CDK4
    |
    HER-2 positive • ER positive
    |
    Herceptin (trastuzumab) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • everolimus • Verzenio (abemaciclib) • Kisqali (ribociclib) • ipatasertib (RG7440) • Itovebi (inavolisib) • giredestrant (GDC-9545) • Pegasys (pegylated interferon α -2a) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • samuraciclib (CT7001)
    Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer (NCI-2018-01050) (NCT03774472)
    Phase 1/2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    02/17/2025
    Initiation :
    08/20/2018
    Primary completion :
    04/17/2024
    Completion :
    04/17/2024
    HER-2 • ER
    |
    ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive
    |
    Ibrance (palbociclib) • letrozole • hydroxychloroquine
    PALbociclib CoLlaborative Adjuvant Study (PALLAS) (NCT02513394)
    Phase 3
    Alliance Foundation Trials, LLC.
    Active, not recruiting
    Last update posted :
    02/14/2025
    Initiation :
    08/01/2015
    Primary completion :
    11/01/2020
    Completion :
    12/01/2028
    HER-2 • PGR
    |
    HER-2 negative
    |
    Ibrance (palbociclib)
    Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (CodeBreak101) (NCT04185883)
    Phase 1
    Amgen
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    12/17/2019
    Primary completion :
    04/29/2026
    Completion :
    03/13/2028
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Mekinist (trametinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Ibrance (palbociclib) • carboplatin • paclitaxel • docetaxel • 5-fluorouracil • everolimus • Vectibix (panitumumab) • Lumakras (sotorasib) • pemetrexed • oxaliplatin • irinotecan • leucovorin calcium • batoprotafib (TNO155) • vociprotafib (RMC-4630) • BI 1701963 • loperamide • zeluvalimab (AMG 404)
    Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC (NCT03439735)
    Phase 2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    07/20/2018
    Primary completion :
    08/01/2025
    Completion :
    11/01/2025
    HER-2 • ER • PGR
    |
    HER-2 negative
    |
    Ibrance (palbociclib)
    Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients with Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery (NCT02760030)
    Phase 2
    Ohio State University Comprehensive Cancer Center
    Active, not recruiting
    Last update posted :
    02/12/2025
    Initiation :
    02/16/2017
    Primary completion :
    07/31/2025
    Completion :
    07/31/2025
    HER-2 • ER • PGR
    |
    HER-2 negative
    |
    Ibrance (palbociclib) • fulvestrant
    A Phase 1/2 Trial of ARV-471 Alone and in Combination with Palbociclib (IBRANCE®) in Patients with ER+/HER2- Locally Advanced or Metastatic Breast Cancer (VERITAC) (NCT04072952)
    Phase 1/2
    Arvinas Estrogen Receptor, Inc.
    Active, not recruiting
    Last update posted :
    02/11/2025
    Initiation :
    08/05/2019
    Primary completion :
    09/13/2024
    Completion :
    03/13/2025
    HER-2
    |
    HER-2 negative
    |
    Ibrance (palbociclib) • vepdegestrant (ARV-471)
    A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies (HERKULES-3) (NCT05039177)
    Phase 1/2
    Erasca, Inc.
    Active, not recruiting
    Last update posted :
    02/11/2025
    Initiation :
    09/20/2021
    Primary completion :
    08/01/2025
    Completion :
    12/01/2025
    KRAS • BRAF • NRAS
    |
    BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600
    |
    Erbitux (cetuximab) • Ibrance (palbociclib) • Braftovi (encorafenib) • ERAS-007
    Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16) (NCT05178888)
    Phase 1
    Mirati Therapeutics Inc.
    Completed
    Last update posted :
    02/11/2025
    Initiation :
    01/20/2022
    Primary completion :
    06/15/2023
    Completion :
    12/30/2024
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Ibrance (palbociclib) • Krazati (adagrasib)
    PLATFORM Study of Precision Medicine for Rare Tumors (NCT04423185)
    Phase 2
    Cancer Institute and Hospital, Chinese Academy ...
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    08/15/2020
    Primary completion :
    07/01/2026
    Completion :
    07/01/2028
    EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A
    |
    BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification
    |
    Xalkori (crizotinib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • imatinib • Tyvyt (sintilimab) • Alecensa (alectinib) • Zejula (niraparib) • Irene (pyrotinib) • Ameile (aumolertinib) • Vizimpro (dacomitinib)
    Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation (NCI-2018-01218) (NCT03065387)
    Phase 1
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    10/31/2017
    Primary completion :
    10/01/2025
    Completion :
    10/01/2025
    HER-2 • KRAS • ERBB3 • ERBB4
    |
    KRAS mutation • EGFR mutation • HER-2 amplification • EGFR amplification
    |
    Mekinist (trametinib) • Ibrance (palbociclib) • everolimus • Nerlynx (neratinib)
    Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCI-MATCH) (NCT02465060)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    08/17/2015
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    MSI • CD4
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bicalutamide • leucovorin calcium • bendamustine • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • GSK2636771 • Zirabev (bevacizumab-bvzr) • defactinib (VS-6063) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Provenge (sipuleucel-T) • TQB2440 (pertuzumab biosimilar) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • BCD-178 (pertuzumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)
    WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor (NCT03854903)
    Phase 1
    Georgetown University
    Completed
    Last update posted :
    02/06/2025
    Initiation :
    04/01/2019
    Primary completion :
    11/01/2023
    Completion :
    01/09/2025
    HER-2 • ER • PGR
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Ibrance (palbociclib) • fulvestrant • Bosulif (bosutinib)
    Study of AVZO-021 in Patients with Advanced Solid Tumors (ARTS-021-1001) (NCT05867251)
    Phase 1/2
    Avenzo Therapeutics, Inc.
    Recruiting
    Last update posted :
    02/05/2025
    Initiation :
    08/30/2023
    Primary completion :
    01/31/2028
    Completion :
    01/31/2030
    HER-2 • CCNE1
    |
    HER-2 negative
    |
    Ibrance (palbociclib) • carboplatin • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • letrozole • Trodelvy (sacituzumab govitecan-hziy) • AVZO-021
    A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) (NCT06065748)
    Phase 3
    Hoffmann-La Roche
    Recruiting
    Last update posted :
    02/05/2025
    Initiation :
    12/11/2023
    Primary completion :
    07/30/2026
    Completion :
    12/30/2028
    HER-2 • ER • CDK4
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive • HER-2 negative + ER positive + ESR1 mutation
    |
    Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • giredestrant (GDC-9545)
    A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (INAVO120) (NCT04191499)
    Phase 2/3
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    01/29/2020
    Primary completion :
    09/29/2023
    Completion :
    09/30/2030
    HER-2 • PIK3CA
    |
    HER-2 negative • PIK3CA mutation
    |
    Ibrance (palbociclib) • fulvestrant • Itovebi (inavolisib)
    Study of PF-07248144 in Advanced or Metastatic Solid Tumors (C4551001) (NCT04606446)
    Phase 1
    Pfizer
    Recruiting
    Last update posted :
    02/04/2025
    Initiation :
    11/16/2020
    Primary completion :
    08/13/2025
    Completion :
    03/07/2027
    HER-2 • ER • CDKN2A
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive
    |
    Ibrance (palbociclib) • fulvestrant • letrozole • atirmociclib (PF-07220060) • prifetrastat (PF-07248144)
    Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma (NCT02159755)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    05/20/2014
    Primary completion :
    06/25/2018
    Completion :
    01/20/2026
    CCND1 • CD5
    |
    Chr t(11;14)
    |
    Ibrance (palbociclib) • Imbruvica (ibrutinib)
    Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) (NCT03155620)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    07/31/2017
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    BRAF
    |
    Lynparza (olaparib) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Vitrakvi (larotrectinib) • Koselugo (selumetinib) • Balversa (erdafitinib) • Retevmo (selpercatinib) • Ensacove (ensartinib) • Zarnestra (tipifarnib) • Tazverik (tazemetostat) • ulixertinib (BVD-523) • samotolisib (LY3023414)
    First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer (ReDiscover) (NCT05216432)
    Phase 1
    Relay Therapeutics, Inc.
    Recruiting
    Last update posted :
    01/29/2025
    Initiation :
    12/08/2021
    Primary completion :
    12/31/2025
    Completion :
    08/31/2026
    HER-2 • PIK3CA • BRCA1 • BRCA2
    |
    HER-2 negative • PIK3CA mutation
    |
    Ibrance (palbociclib) • Piqray (alpelisib) • Kisqali (ribociclib) • fulvestrant • RLY-2608 • atirmociclib (PF-07220060)
    Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer (NCT02778685)
    Phase 2
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    01/29/2025
    Initiation :
    09/30/2016
    Primary completion :
    03/30/2026
    Completion :
    03/30/2026
    HER-2 • ER
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • Ibrance (palbociclib) • fulvestrant • letrozole
    TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (NCT02693535)
    Phase 2
    American Society of Clinical Oncology
    Recruiting
    Last update posted :
    01/29/2025
    Initiation :
    03/14/2016
    Primary completion :
    06/30/2026
    Completion :
    06/30/2027
    BRAF
    |
    ER positive • HER-2 negative • PGR positive
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Xalkori (crizotinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Rozlytrek (entrectinib) • sunitinib • tamoxifen • Perjeta (pertuzumab) • Cotellic (cobimetinib) • Bavencio (avelumab) • Talzenna (talazoparib) • Verzenio (abemaciclib) • albumin-bound paclitaxel • cyclophosphamide • Stivarga (regorafenib) • fulvestrant • Lytgobi (futibatinib) • Tukysa (tucatinib) • Torisel (temsirolimus) • letrozole • Inlyta (axitinib) • epirubicin • anastrozole • exemestane • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • leuprolide acetate for depot suspension
    Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor (NCT04966481)
    Phase 3
    Washington University School of Medicine
    Recruiting
    Last update posted :
    01/29/2025
    Initiation :
    04/06/2022
    Primary completion :
    02/28/2027
    Completion :
    02/28/2027
    CDKN2A
    |
    CDKN2A negative
    |
    Erbitux (cetuximab) • Ibrance (palbociclib)
    Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (PATINA) (NCT02947685)
    Phase 3
    Alliance Foundation Trials, LLC.
    Active, not recruiting
    Last update posted :
    01/13/2025
    Initiation :
    06/21/2017
    Primary completion :
    10/15/2024
    Completion :
    07/31/2026
    PIK3CA • PGR
    |
    HER-2 positive • HR positive • PIK3CA mutation
    |
    Herceptin (trastuzumab) • Ibrance (palbociclib) • Perjeta (pertuzumab) • fulvestrant • letrozole • anastrozole • exemestane
    Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) (NCT06757634)
    Phase 3
    Celcuity Inc
    Not yet recruiting
    Last update posted :
    01/07/2025
    Initiation :
    06/30/2025
    Primary completion :
    12/31/2027
    Completion :
    12/30/2028
    PIK3CA
    |
    Ibrance (palbociclib) • Kisqali (ribociclib) • fulvestrant • gedatolisib (PF-05212384)
    To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer (GO39374) (NCT03006172)
    Phase 1
    Genentech, Inc.
    Active, not recruiting
    Last update posted :
    12/20/2024
    Initiation :
    12/13/2016
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    HER-2 • PIK3CA
    |
    HER-2 negative • PIK3CA mutation
    |
    Herceptin (trastuzumab) • Ibrance (palbociclib) • Perjeta (pertuzumab) • fulvestrant • letrozole • metformin • Itovebi (inavolisib)
    Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion (NCT06739395)
    Phase 2
    Tianjin Medical University Second Hospital
    Recruiting
    Last update posted :
    12/18/2024
    Initiation :
    11/01/2024
    Primary completion :
    12/31/2026
    Completion :
    05/01/2027
    BRAF
    |
    Lynparza (olaparib) • Mekinist (trametinib) • Ibrance (palbociclib) • Tafinlar (dabrafenib) • Focus V (anlotinib) • temozolomide • Lenvima (lenvatinib) • Piqray (alpelisib) • pazopanib • Epidaza (chidamide) • Trodelvy (sacituzumab govitecan-hziy) • bozitinib (APL-101)
    To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH) (NCT03644186)
    Phase 2
    ETOP IBCSG Partners Foundation
    Completed
    Last update posted :
    12/13/2024
    Initiation :
    04/16/2019
    Primary completion :
    01/03/2023
    Completion :
    04/14/2023
    HER-2 • ER
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • Ibrance (palbociclib) • paclitaxel • Perjeta (pertuzumab) • letrozole
    A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer (TRAK-ER) (NCT04985266)
    Phase 2
    Royal Marsden NHS Foundation Trust
    Recruiting
    Last update posted :
    12/05/2024
    Initiation :
    03/30/2022
    Primary completion :
    09/01/2027
    Completion :
    09/01/2030
    HER-2
    |
    HER-2 negative
    |
    Ibrance (palbociclib) • tamoxifen • fulvestrant • letrozole • anastrozole • exemestane
    Palbociclib and Pembrolizumab in Central Nervous System Metastases (NCT02896335)
    Phase 2
    Massachusetts General Hospital
    Recruiting
    Last update posted :
    11/21/2024
    Initiation :
    02/02/2017
    Primary completion :
    09/01/2025
    Completion :
    09/01/2026
    CDKN2A • CCND1 • CCNE1 • CDK4 • CDK6 • CCND2 • CCND3
    |
    CCNE1 amplification • CCND1 amplification • CDK4 amplification
    |
    Keytruda (pembrolizumab) • Ibrance (palbociclib)
    Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (NCT03297606)
    Phase 2
    Canadian Cancer Trials Group
    Recruiting
    Last update posted :
    11/12/2024
    Initiation :
    03/23/2018
    Primary completion :
    01/31/2026
    Completion :
    01/31/2027
    BRAF
    |
    Opdivo (nivolumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Xalkori (crizotinib) • erlotinib • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Zelboraf (vemurafenib) • sunitinib • Perjeta (pertuzumab) • Cotellic (cobimetinib) • Bosulif (bosutinib) • Tukysa (tucatinib) • Torisel (temsirolimus) • Inlyta (axitinib) • Erivedge (vismodegib)
    A Study to Learn About How Medicines Called CDK4/6 Inhibitors Are Used in People With Advanced or Metastatic Breast Cancer in Australia (ROSIE) (NCT06624020)
    Phase N/A
    Pfizer
    Completed
    Last update posted :
    10/02/2024
    Initiation :
    05/20/2024
    Primary completion :
    07/31/2024
    Completion :
    07/31/2024
    CDK4
    |
    Ibrance (palbociclib)
    Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors (PEARL) (NCT02028507)
    Phase 3
    Spanish Breast Cancer Research Group
    Completed
    Last update posted :
    09/25/2024
    Initiation :
    03/13/2014
    Primary completion :
    01/14/2019
    Completion :
    01/11/2021
    HER-2 • ER • PGR
    |
    HER-2 negative • ESR1 mutation
    |
    Ibrance (palbociclib) • capecitabine • fulvestrant • exemestane
    Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast (NCT03304080)
    Phase 1/2
    Icahn School of Medicine at Mount Sinai
    Active, not recruiting
    Last update posted :
    08/01/2024
    Initiation :
    12/20/2017
    Primary completion :
    07/31/2025
    Completion :
    12/31/2025
    HER-2 • PGR
    |
    HER-2 positive • HER-2 amplification
    |
    Herceptin (trastuzumab) • Ibrance (palbociclib) • Perjeta (pertuzumab) • anastrozole
    A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (BOUQUET) (NCT04931342)
    Phase 2
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    06/13/2024
    Initiation :
    10/07/2021
    Primary completion :
    05/30/2028
    Completion :
    12/31/2028
    ER
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • paclitaxel • Kadcyla (ado-trastuzumab emtansine) • Cotellic (cobimetinib) • Verzenio (abemaciclib) • cyclophosphamide • letrozole • ipatasertib (RG7440) • triptorelin • goserelin acetate • Itovebi (inavolisib) • giredestrant (GDC-9545)
    First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting. (PERFORM) (NCT04767594)
    Phase N/A
    Pfizer
    Recruiting
    Last update posted :
    06/07/2024
    Initiation :
    10/27/2020
    Primary completion :
    04/03/2028
    Completion :
    04/03/2028
    HER-2
    |
    HER-2 negative
    |
    Ibrance (palbociclib) • fulvestrant • exemestane